Global human recombinant insulin market is expected to showcase a growth rate of 7.8% to reach US$ 64 Bn market size by 2030.

Global human recombinant insulin market is a consolidated industry with a few organizations occupying majority of the market share. These organizations operate globally with foothold in every major countries as a standalone entity or operate in collaboration with other players. Some of these organizations are Novo Nordisk A/S, Eli Lilly and Company, and Sanofi S.A. among others Some of the industry features include over dependability on specific technologies and products, capital and complex technologies causing barriers to new entrants, high costs of products, and moderate research and development

Industry drivers and trends:

Increasing prevalence of diabetes is major driving factor behind growth of the industry. For instance, according to Centres for Disease Control and Prevention (CDC), in 2019, there were 28.7 million people of all ages had diagnosed with diabetes in the US. Moreover, Industry developments such as product launches,  acquisitions and collaborations are expected to support market growth over the forecast period. For instance, in 2022, Novo Nordisk launched Tresiba Biologic Analog Insulin to expand affordability options.

Key Takeaways:

North America region occupies highest market share in the global human recombinant insulin market Technological advancements into insulin delivery devices is expected to support growth of the market over the forecast period Advancements in product formulations is another factors supporting growth of the market. For instance, Flasp (NovoNordisk) is a insulin aspart formulation with improved initial absorption of the drug. Moreover, oral insulin research is also underway which could potentially disrupt the insulin industry Consolidated nature of the industry and aggressive patent protection strategies employed by leading players has diminished the entry of biosimilar players in the market resulting in high costs of the products

Segments Covered in the report:

The global Human Recombinant Insulin Market is segmented based on product type, brand, distribution channel, and region as follows:

• Product Type (Revenue, USD Billion; 2022–2030)
  • Rapid-Acting Human Insulin
  • Short-Acting Human Insulin
  • Intermediate-Acting Human Insulin
  • Long-Acting Human Insulin
  • Premixed Human Insulin
• Brand Product (Revenue, USD Billion; 2022–2030)
  • Humalog
  • Novolog
  • Apidra
  • Humulin R
  • Novolin R
  • Humulin N
  • Novolin N
  • Levemir
  • Lantus
  • Humalog Mix
  • Novolog Mix
  • Others
• Distribution Channel (Revenue, USD Billion; 2022–2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region (Revenue, USD Billion; 2022–2030)
  • North America 
    • U.S.
    • Canada
  • Europe 
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific 
    • China
    • Japan
    • South Korea
    • India
    • ASEAN
    • Rest of APAC
  • Latin America 
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa 
    • Saudi Arabia
    • UAE
    • Rest of MEA

Definition:

The global human recombinant insulin market is the market for all products and services related to the production, distribution, and use of human recombinant insulin. Human recombinant insulin is a type of insulin that is produced using recombinant DNA technology. It is identical to the insulin that is naturally produced by the human body, and it is used to treat diabetes.